two ELISAs for quantifying complexes of prostate-specific antigen (PSA) with a2-macroglobulin (a2M), using partially purified PSAa2M complex as the calibrator. One EUSA was designed to evaluate PSkCS2M complex in fluids containing a huge excess of PSA over the amount of complex (semen-derived fluids), the other for use in fluids containing an excess of a2M over PSA (blood plasma). The range of the assays was 2-1000 g/L for PSA complexed to t52M; the detection limit was 3 &g/L. Intra-and interassay CVs were 7-13% and 11-17%, respectively, When purified PSA was incubated with citrated plasma, between 45% and 65% of the added PSA was recovered as free PSA, whereas -25% funned complexes with a2M, 10% complexed with a5-antichymotrypsin,, 
protease very similar to the enzymes of the glandular kallikrein family [3] [4] [5] . However, unlike other proteins of this family, PSA has chymotrypsin-like activity with strict substrate specificity [4] [5] [6] [7] . PSA seems to be involved directly in the liquefaction of the seminal coagulum formed at ejaculation [4, 6] . Quantification of PSA has received great interest because of the important role of this marker for diagnosing prostate carcinoma and monitoring the attendant therapy [8] [9] [10] [11] [12] . However, concentrations of serum PSA are also increased in some patients with benign prostatic hyperplasia [13, 14] , whereas a large percentage of patients with clinically localized prostate cancer have serum PSA concentrations within the normal range [15/ . These factors decrease the specificity and sensitivity of the PSA assays.
In prostate cancer patients, free, noncomplexed PSA reportedly is a minor fraction in serum [16] , the PSA in blood binding mainly to a1-antichymotrypsin (a,ACT) [16] [17] [18] [19] . Indirect evidence suggests that PSA might also bind to a2-macroglobulin-(a2M). Both the free form of PSA and the a1ACT-bound form are detectable by current immunoassays, but PSA bound to a2M is probably engulfed in the a2M structure, rendering it undetectable at present. Therefore, the total PSA measured by the available immunoassays consists of the sum of free PSA and the PSA complexed to a1ACT (PSA:a1ACT), the latter representing the major portion. Although protein C inhibitor (PCI) forms complexes with PSA in seminal plasma [20] [21] [22] and in a purified system [22] , no PSA:PCI complex was detected in the plasma from prostate cancer patients with very high PSA concentrations [21] .
Several groups have shown that calculation of the free PSA/total PSA ratio or the complexed PSA/total PSA ratio provides a better discrimination between benign prostate hyperplasia and prostate cancer [16-18, 23, 24] . To date, investigators have taken for granted that PSA:a2M complex is not detectable by immunoassays [16, 17, 19, 25] . They assumed this because, when purified PSA is added to purified ct,M, -50-75% of the PSA immunoreactivity (the active PSA fraction) is lost, whereas PSA added to inactivated a2M does not show this loss of recovery. For PSA to be detected by a sandwich ELISA, at least two epitopes in the PSA molecule must be accessible to the capture and detection anti-PSA antibodies. However Semen was incubated at 37 #{176}C for 3 h and then centrifuged at 10 000g for 4 mm at 20 #{176}C. Prostatic fluid and seminal vesicle secretion were collected postmortem from men at autopsy within 18 h of death, centrifuged at 13 000g for 2 mm, and stored at -80 #{176}C, if not used immediately.
Single blood samples were obtained from apparently healthy donors (5 men and 35 women). Plasma was pooled from 25 apparently healthy male donors. Thirty patients with prostate disease and 20 healthy women were also included in the study. Blood was anticoagulated with 0.13 mmol/L trisodium citrate (9:1, by vol) and without delay centrifuged at 2SOOg for 20 mm at 4#{176}C. All samples were stored at -80 #{176}C until assayed. The stability of the PSAa2M complex after several cycles of freezing and thawing and after storage at various temperatures was studied with 10 seminal samples and 10 plasma samples (from 5 men and 5 women) to which purified PSA:a2M had been added to yield a wide range of concentrations of the complex. Wilmington, NC) at 500/mm. In method A, specific rabbit anti-a2M (IgG fraction) diluted to 50 mg/L in coating buffer was used to coat microtiter plates overnight at 4 #{176}C. Thereafter, the wells were washed five times with 220 p.L of blocking buffer and blocked with 300 .tL of blocking buffer for at least 1 h at 37 #{176}C. We then transferred into each well in duplicate 50 L of samples diluted to convenient concentrations with blocking buffer and incubated the plates at room temperature for 2 h. After washing the plates three times with blocking buffer and three times with conjugate buffer, we incubated them for a further I h at room temperature Elution volume, mL
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In method B, the capture and detection antibodies were interchanged, and undiluted female plasma was added as an additional negative control. The detection limit of the PSA:cs2M assays was defined as the concentration of complex that gave an absorbance equal to that of the assay buffer + 2 SD (calculated from 15 replicates). amounts of free a,M, so the amount of a2M in the complex cannot be used for calculating the amount of PSA:a2M complex. By using an excess of PSA as indicated above, we can separate free PSA from complexed PSA, measure the amount of PSA that remains in the free form, and indirectly calculate the amount of PSA complexed to a2M. To assess the validity of this approach, we treated an aliquot of the preparation of PSA:a2M obtained as described above (25 mg/L PSA complexed to a2M) with dithiothreitol and iodoacetic acid to expose most of the PSA antigen determinants Left 3-800 gJL (final concentration) PSAcomplexed with a2M (partially purified complex) was added to blocking buffer (#{149}). Also, 290 .tL of seminal plasma containing 402 1zg/L PSA complexed to a2M was mixed with 10 gL of PSA:a2M complex containing 6000 gtgJL PSA complexed to cr2M, and the mixture was serially diluted with blocking buffer (0). Samples were assayed for PSA:a2M complex with method A as described in Materials and Methods. Right 3-800 pJL (final concentration)PSA complexed with a2M (partially purified complex) was added to blocking buffer (#{149}) or to normal blood plasma 10), and samples were assayed for PSA:a2M complex with method B as described in Materials and Methods.
In vitro formation
seminal fluid from a single individual that had been incubated for 3 h at 37 #{176}C and that initially contained 402 .tgfL PSA complexed to a2M, the plot of absorbance against serial dilutions of the mixture was parallel to the calibration curve of purified PSAa2M complex diluted in blocking buffer ( Fig. 2,  left; method A) , and --110% of the complex added was recovered in the assay. In all cases, the background signal for buffer and negative controls was 0.0005 M/min or less.
The detection limit of the assays was 3 p.g/L PSA complexed to a2M. This corresponds to a biological detection limit in plasma samples of 6 g/L, because optimal results are obtained when test plasma is diluted at least twofold. The intra-and mnterassay CVs for PSA complexed to a2M were 7-14% and 11-19%, respectively, at complexed PSA concentrations of
6-500 tg/L (n = 8).
The recovery in the complex assay (method A) after addition of 10-400 &g/L PSA complexed with a2M to seminal plasma ranged from 97% to 117%, whereas the recovery in blood plasma (method B) ranged from 89% to 108%. This overestimation of the PSA:a2M added to seminal fluid may represent the complex formed between the PSA in the seminal fluid and some molecules of a2M in the purified complex that still have free reactive centers.
The stability of the PSA:a2M complex was studied in seminal fluid and in blood plasma samples to which purified PSA:a2M
had been added to give 6-500 .tg/L PSA complexed to a2M. The recovery was 85-107% after 4 days at 4 #{176}C, 65-93% after 4 days at room temperature, and 88-110% after freezing and thawing the samples four times.
The ELISA for PSAa2M complex (method A) was used to detect and quantify complexes in seminal fluid and in prostatic and seminal vesicle fluids. 21.1 ± 6.4 3 ± 2 4 ± 3 PSA:a1ACT#{176} 1.6 ± 0.9 2.5 ± 1.9 0.1 ± 0.1 PSA:a2M#{176} 2.5 ± 2.6 6.5 ± 2. 1050 MgIL (median, 25 .tg/L). However, there was no correlation between the concentrations of total PSA and those of PSA complexed to a2M. For example, two patients with 12 900 and 5320 j.tgfL total PSA had <6 and 20 g/L PSA complexed to a2M, respectively, whereas two patients with 1.9 and 14 jLgfL total PSA had 56 and 240 pg/L PSA complexed to a,M, respectively.
None of the 20 plasma samples from healthy women had detectable PSA:a2M complex.
Discussion
When purified PSA is added to blood plasma, most of the active PSA complexes to a,M and is1ACT, and the immunoreactivity of the PSA complexed to a2M is lost [27] . However, Christensson et al.
[27] were able to trace the PSA bound to a2M by means of gel filtration, using '251-labeled PSA and immunoblotting, and found that 40% of the PSA was comp!exed to a2M, 20% complexed to a1ACT, and 20% was free. Therefore, some have speculated that patients with prostate disease and detectable serum PSA have circulating PSA:a2M complexes. However, no assay for quantifying PSA:a2M complex has been reported, despite its potential clinical significance.
Here, we present an ELISA specific for PSA:a2M complexes that is able to detect as little as 3 g/L PSA in complex with a2M. Using this assay (method A), we have identified and quantified PSA:a2M complexes in seminal plasma and in seminal vesicle and prostatic fluids. Our results show that seminal plasma contains substantial amounts of PSA:a2M complex, although the major portion of PSA is complexed to PCI, probably because of the higher concentration of PCI in semen. Our results also show that both a1ACT and a2M are present in prostatic and seminal vesicle fluids.
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